ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 2834 • 2015 ACR/ARHP Annual Meeting

    CXCL10 Expression Is Elevated in Synovial Fluid of Psoriatic Arthritis Patients

    Anastasiya Muntyanu1, Fatima Abji2, Kun Liang3, Vinod Chandran4 and Dafna Gladman4, 1Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 2Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 3Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, 4Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Psoriatic arthritis (PsA), an inflammatory musculoskeletal disease, develops in approximately 30% of patients with psoriasis. We previously identified C-X-C motif chemokine 10 (CXCL10) as…
  • Abstract Number: 168 • 2015 ACR/ARHP Annual Meeting

    Ultrasound Evaluation of the Efficacy of Biologic and Targeted Synthetic Dmards Toward Rheumatoid Arthritis Patients: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort in Japan

    Ayako Nishino1,2, Shin-ya Kawashiri1,2, Atsushi Kawakami1,2, Tamami Yoshitama2, Nobutaka Eiraku2, Noki Matsuoka2, Yukitaka Ueki2, Akitomo Okada2, Hiroaki Hamada2, Toshihiko Hidaka2, Shuji Nagano2, Tomomi Tsuru2, Keita Fujikawa2 and Yojiro Arinobu2, 1Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, 2Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan

    Background/Purpose: Few prospective ultrasound (US) cohort studies of rheumatoid arthritis (RA) patients treated by biologic or targeted synthetic DMARDs (b/tsDMARDs) are reported. We have been…
  • Abstract Number: 574 • 2015 ACR/ARHP Annual Meeting

    Metabolomic Profiling Predicts Outcome of Rituximab Therapy in Rheumatoid Arthritis

    Shannon Sweeney1, Arthur Kavanaugh2, Alessia Lodi3, Bo Wang1, David L. Boyle4, Stefano Tiziani5 and Monica Guma6, 1University of Texas at Austin, Austin, TX, 2University of California San Diego, La Jolla, CA, 3nutritional Sciences, University of Texas at Austin, Austin, TX, 4Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, 5Nutritional Sciences, University of Texas at Austin, Austin, TX, 6Pharmacology, University of California, San Diego, La Jolla, CA

    Background/Purpose: We hypothesized that characterization of patients’ metabolic profiles, utilizing both high-resolution 1H-nuclear magnetic resonance (NMR) and mass spectrometry (MS), might help predict response to…
  • Abstract Number: 1021 • 2015 ACR/ARHP Annual Meeting

    Nucleic Acids Sensing Receptors RIG-I and MDA5 As Potential Amplifiers of the Interferon Signature in Childhood Onset Systemic Lupus Erythematosus

    Naomi I Maria1, M. Javad Wahadat1, Cornelia G. van Helden-Meeuwsen1, Annette van Dijk-Hummelman2, Radboud JEM Dolhain3, Sylvia Kamphuis2 and Marjan A. Versnel1, 1Immunology, Erasmus Medical Center, Rotterdam, Netherlands, 2Pediatric Rheumatology, Eramus MC Sophia Children's Hospital, Rotterdam, Netherlands, 3Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands

    Background/Purpose: Defective or sustained activation of Interferon (IFN) signaling has been associated with enhanced susceptibility to systemic lupus erythematosus (SLE). The cytosolic RIG-I-like receptors (RLRs),…
  • Abstract Number: 1575 • 2015 ACR/ARHP Annual Meeting

    Serum Vascular Cell Adhesion Molecule-1 (VCAM-1) Levels Are Associated with Vascular Dysfunction and Increased Cardiovascular Risk in an Animal Model and Patients with Rheumatoid Arthritis

    Ruth Davies1, Daniela Iacono2, Lauren A. Jordan1, Jessica O Williams1, Charlotte Rawlings1, Derek Lang3, Anwen S. Williams1 and Ernest H. Choy1, 1Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, 2Department of Clinical and Experimental Medicine. Rheumatology Section. Second University of Naples, Naples, Italy, 3Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom

    Background/Purpose:  Mortality is increased in Rheumatoid arthritis (RA) patients mainly due to cardiovascular (CV) disease; however the biologic mechanisms are unknown. Increased CV risk in…
  • Abstract Number: 1917 • 2015 ACR/ARHP Annual Meeting

    Developing and Validating a Serum Biomarker for the Extent of Skin Disease in Patients with Diffuse Cutaneous Systemic Sclerosis

    Lisa Rice1, Julio Mantero2, Giuseppina Stifano1, Jessica Ziemek3, Robyn T. Domsic4 and Robert Lafyatis1, 1Boston University School of Medicine, Boston, MA, 2Rheumatology, Boston University School of Medicine, Boston, MA, 3Rheumatology/Arthritis Center, Boston University School of Medicine, Boston, MA, 4Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: In this study we aimed to both agonistically investigate alterations in the serum proteome of patients with diffuse cutaneous systemic sclerosis (dcSSc), as well…
  • Abstract Number: 2584 • 2015 ACR/ARHP Annual Meeting

    Prediction of Disease Relapses By Multi-Biomarker Disease Test Activity in Rheumatoid Arthritis Patients Tapering DMARD Treatment

    Juergen Rech1, Axel J. Hueber2, Matthias Englbrecht2, Stephanie Finzel3, Judith Haschka4,5, Bernhard Manger2, Arnd Kleyer3, Michaela Reiser3, Hans-Peter Tony6, Stefan Kleinert7, Martin Feuchtenberger8, Martin Fleck9, Karin Manger10, Wolfgang Ochs11, Matthias Schmitt-Haendle12, Joerg Wendler13, Florian Schuch13, Monika Ronneberger13, Hanns-Martin Lorenz14, Hubert Nüßlein15, Rieke Alten16, Jayme Fogagnolo Cobra17, Joerg C. Henes18, Klaus Krüger19 and Georg A. Schett20, 1medical clinic 3, University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 3Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, 4Medical Department 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 5Medical Department II, Medical University of Vienna, St. Vincent Hospital Vienna,, Vienna, Austria, 6University Hospital Würzburg, Würzburg, Germany, 7Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, 8Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, 9Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany, 10Rheumatology Practice Bamberg, Bamberg, Germany, 11Rheumatologist in Private Practice, Bayreuth, Germany, 12Rheumatology Practice, Bayreuth, Germany, 13Schwerpunktpraxis Rheumatologie, Erlangen, Germany, 14University Hospital Heidelberg, Heidelberg, Germany, 15University Erlangen, Nürnberg, Germany, 16Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 17Instituto de Reumatologia de Sao Paolo, Sao Paolo, Brazil, 18Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, 19Praxiszentrum St. Bonifatius, München, Germany, 20University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: To analyze the role of multi-biomarker disease activity (MBDA) in predicting disease relapses in rheumatoid arthritis (RA) patients in sustained remission, tapering disease modifying…
  • Abstract Number: 2965 • 2015 ACR/ARHP Annual Meeting

    Might Troponin be a Marker for Subclinical Scleroderma Heart Involvement (SHI)?

    Chiara Stagnaro1, Anna d'Ascanio1, Alice Parma2, Umberto Conti3, Michele Emdin4, Alessandra Della Rossa1 and Marta Mosca1, 1Internal Medicine, University of Pisa, Pisa, Italy, 2University of Pisa, Pisa, Italy, 3Cardiotoracico, Cardiologia 2, Pisa, Italy, 4Fondazione Toscana Gabriele Monasterio, UOC Cardiologia e Medicina Cardiovascolare, Pisa, Italy

    Background/Purpose: Systemic sclerosis (SSc) is a rare connective tissue disease with pronounced alterations of the microvascular system, frequent cellular and humoral immunity abnormalities and fibroblast…
  • Abstract Number: 171 • 2015 ACR/ARHP Annual Meeting

    Serum Calprotectin Levels Correlate with Ultrasonographic Synovitis in Rheumatoid Arthritis Patients

    Jana Hurnakova1, Jakub Zavada1, Petra Hanova1, Hana Hulejová1, Martin Klein1, Herman F Mann1, Olga Sleglova1, Marta Olejarova1, Šárka Forejtová1, Olga Ruzickova1, Martin Komarc2, Jiri Vencovsky1, Karel Pavelka1 and Ladislav Senolt1, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 2Institute of Biophysics and Informatics of the First Faculty of Medicine, Charles University, Prague, Czech Republic

    Background/Purpose: Calprotectin (S100A8/9, MRP8/14) has been demonstrated as a promising biomarker of clinical and laboratory disease activity in rheumatoid arthritis (RA). In addition, two small…
  • Abstract Number: 583 • 2015 ACR/ARHP Annual Meeting

    A Serological Biomarker of Active MMP3, but Total MMP3, Can Early Assess Treatment Efficacy and Differentiate Doses of Tocilizumab and an Early Change in Active MMP3, but Not Total MMP3, Is Associated with Radiographic Change at 1 Year

    Anne Sofie Siebuhr1, Stephanie Nina Kehlet2, Kishwar Musa2, Inger Byrjalsen3, Morten Asser Karsdal4 and Anne C. Bay-Jensen5, 1Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 2Laboratory, Nordic Bioscience, Herlev, Denmark, 3Research & Development, Nordic Bioscience, Herlev, Denmark, 4Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 5Biomarkers and Research, Rheumatology, Nordic Bioscience, Herlev, Denmark

    Background/Purpose: Protease activity, especially MMP3, is known to be increased with arthritis, such as rheumatoid arthritis. MMP3 is mainly expressed by fibroblasts; a key cell…
  • Abstract Number: 1023 • 2015 ACR/ARHP Annual Meeting

    Tumor Necrosis Factor-a (TNF-a) and Interferon Gamma Inducible Protein-10 (IP-10) As Predictors of Active Disease Status in Localized Scleroderma

    Kathryn S. Torok1, Jonathan Yabes2, Qi Mi3, Christina Kelsey1 and Kelsey Magee4, 1Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 2Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 3Department of Sports Medicine and Nutrition, University of Pittsburgh, Pittsburgh, PA, 4Pediatrics, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose:   Localized scleroderma has both inflammatory and fibrotic components contributing to its effect on the skin and underlying tissue.   The extent and duration of…
  • Abstract Number: 1579 • 2015 ACR/ARHP Annual Meeting

    Association of Myocardial Abnormalities with N-Terminal Pro-Brain Natriuretic Peptide and Disease Activity in Rheumatoid Arthritis without Cardiac Symptoms, Assessed By Cardiac Magnetic Resonance Imaging

    Hitomi Kobayashi1, Yasuyuki Kobayashi2, Isamu Yokoe3, Natsumi Ikumi4,5, Hirotake Inomata6, Atsuma Nishiwaki6, Noboru Kitamura1, Kaita Sugiyama6, Hidetake Shiraiwa6, Masataka Nozaki6, Yosuke Nagasawa6, Yoshihiro Matsukawa5 and Masami Takei1, 1Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, 2Advanced Biomedical Imaging Informatics, St.Marianna University School of Medicine, Kawasaki, Japan, 3Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan, 4Nihon University School of Medicine, Shinjuku, Japan, 5Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, 6Nihon University School of Medicine, Tokyo, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is a multi-organ inflammatory disorder associated with high cardiovascular morbidity and mortality. Cardiac involvements are typically clinically silent, only manifesting as…
  • Abstract Number: 1936 • 2015 ACR/ARHP Annual Meeting

    STAT3-Regulated Gene Expression in Circulating CD4+ T Cells Discriminates RA Patients Independently of Clinical Parameters in Early Arthritis: A Validation Study

    Arthur G Pratt1, Amy E. Anderson1, Dennis W Lendrem2, Andrew Skelton2, Jonathan Massey3, Nisha Nair3, Julie Diboll2, Ben Hargreaves2, Philip M Brown2, Anne Barton4,5 and John D Isaacs2, 1Institute of Cellular Medicine (Musculoskeletal Research Group), National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, 2Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, 3NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, 4NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, 5Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom

    Background/Purpose:  A previously described transcriptional signature present in circulating CD4+ T cells of early rheumatoid arthritis (RA) patients implicated STAT3 signalling as an early pathophysiological…
  • Abstract Number: 2594 • 2015 ACR/ARHP Annual Meeting

    Multi-Biomarker Disease Activity Score As a Predictor of Flare in Patients with Rheumatoid Arthritis Who Stop TNF-Alpha-Inhibitor Therapy

    Femke Lamers-Karnebeek1, Marjan Ghiti Moghadam2, Harald E. Vonkeman3, Janneke Tekstra4, Annemarie Schilder5, Henk Visser6, Peter M. ten Klooster7, Eric H. Sasso8, David Chernoff9, Willem Lems10, Dirkjan van Schaardenburg11, Robert Landewé12, Iet Van Albada13, T.R.D.J. Radstake14, Piet van Riel15, Mart A.F.J. van de Laar16 and Tim Jansen17, 1Rheumatology, Radboudumc, Nijmegen, Netherlands, 2rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, 3Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, 4Dept. Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 5Rheumatology, Medisch Centrum Leeuwarden, Leeuwarden, Netherlands, 6Rheumatology, Alysis Care Group, Arnhem, Netherlands, 7Pcgr, University of Twente, Enschede, Netherlands, 8Crescendo Bioscience Inc., South San Francisco, CA, 9Crescendo Bioscience, Inc., South San Francisco, CA, 10Amsterdam Rheumatology and immunology Center, location VU University Medical Center, Department of Rheumatology, Amsterdam, Netherlands, 11Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center, Amsterdam, Netherlands, 12Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, 13Meander MC, Amersfoort, Netherlands, 14Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 15Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 16Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, 17VieCuri Medical Center, Venlo, Netherlands

    Background/Purpose: Prediction which rheumatoid arthritis (RA) patients in low disease activity (LDA) can successfully discontinue TNF inhibition (TNFi) may improve the cost-effectiveness of RA management.…
  • Abstract Number: 2984 • 2015 ACR/ARHP Annual Meeting

    Scleroderma Bronchoalveolar Lavage Fluid Thrombin Activity:  Correlation with Pulmonary Function

    Merrideth Ashley Morris1, Tanjina Akter2, Paul Nietert3, Galina S. Bogatkevich2 and Richard Silver4, 1Medical University of South Carolina, Charleston, SC, 2Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 3Division of Public Health Science, Medical University of South Carolina, Charleston, SC, 4Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Multiple lines of evidence identify thrombin as an important mediator of lung fibrosis in systemic sclerosis (SSc).  In addition to demonstrating dramatically high levels…
  • « Previous Page
  • 1
  • …
  • 86
  • 87
  • 88
  • 89
  • 90
  • …
  • 109
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology